NYNalan Gokce Celebi Yamanoglu

Nalan Gokce Celebi Yamanoglu

*This is an algorithmically generated author record based on publicly available information.

Nalan Gokce Celebi Yamanoglu has a total of 14 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Antitrombotik İlaçların COVID-19 Şiddeti Üzerindeki Profilaktik Etkisi; Retrospektif Gözlemsel Çalışma

    by Ejder Saylav Bora, Adnan Yamanoğlu, Guner Yurtsever, Nalan Gökçe Çelebi̇ Yamanoğlu, Hüseyin Acar, Cüneyt Arikan, Fatih Topal

    Amaç: Antitrombotik ilaçlar ağır COVID-19 hastalarının tedavisinde kendine rutin bir yer edinmiş olmasına rağmen, enfeksiyona maruz kalmadan önce herhangi bir sebeple antitrombotik ilaç kullanımının hastalığın prognozuna ve klinik seyrine bir etkisi olup olmadığı henüz bilinmemektedir. Bu çalışmanın amacı SARS COV-2’ye maruz kalmadan önce antitrombotik ilaç kullanımının hastalığın klinik seyri ve mortalitesi üzerine etkisi olup olmadığını belirlemektir. Gereç ve Yöntemler: Hastanemiz COVID-19 polikliniğine başvuran COVID-19 tanısı yapılan RT-qPCR test sonucu ile doğrulanan ve bir akciğer görüntülemesi ile COVID-19 pnömonisi tanısı alan tüm hastalar çalışmaya dahil edilmiştir. Covid-19 pnömonisi olan hastaların anamnez bilgileri, hastanede ve yoğun bakımda yatış süreleri hastane kayıt sisteminden elde edildi ve kayıt altına alındı. Tüm hastaların klinik sonlanımları; sağkalım veya exitus olarak sınıflandırılarak kayıt altına alındı. Bulgular: PCR testi pozitif olup aynı zamanda viral pnömonisi olan hasta sayısı toplam 415 idi. Hastaların yaş ortalaması 53±19 ve 234’ü (56%) erkek idi. 415 hastanın 168’i (40%) en az bir çeşit antitrombotik ilaç kullanmakta iken 247’si (60%) herhangi bir antitrombotik ilaç kullanmıyordu. COVID-19 öncesi antitrombotik ilaç kullanan 168 hastada mortalite oranı %4,5 iken, antitrombotik kullanmayan 247 hastada mortalite oranı %12,5 olarak bulundu (p=0.008). Antitrombotik ilaç kullanan 168 hastada yoğun bakıma yatış oranı %10,1 iken, antitrombotik kullanmayan 247 hastada yoğun bakıma yatış oranı %13,7 olarak (p=0.31). Sonuç: Erken hastalıkta, özellikle ayaktan hastalarda antitrombotik tedavi, koagülopatiyi ve endotelyal ilişkili hastalığı önleyebilir, ancak trombo-inflamatuar faz sırasında çok geç bir antitrombotik tedavi uygulaması gerekli koruyucu etkiyi sağlamayabilir. Bu hipotezin uygun prospektif randomize çalışmalarda test edilmesi gerekmektedir.

  • Open Access

    The effect of calcium gluconate in the treatment of hyperkalemia

    by Nalan Gokce Celebi Yamanoglu, Adnan Yamanoglu

    OBJECTIVES: Intravenous (IV) calcium salts are routinely recommended as a cardio-protective therapy in the emergency treatment of severe hyperkalemia. However, this recommendation is supported by a low level of evidence and is anecdotal. The aim of this study is to determine the effectiveness of IV Calcium (Ca) gluconate in the treatment of hyperkalemia. MATERIALS AND METHODS: Patients with hyperkalemia and with the electrocardiogram (ECG) changes due to hyperkalemia over a 1 year period were included in this prospective observational study. Patients’ ECGs were measured, before and after IV Ca-gluconate treatment and after normalization of potassium levels. Wilcoxon test and McNemar's test were used to compare the ECG parameters before and after Ca-gluconate therapy. RESULTS: The mean potassium value of 111 patients who met the inclusion criteria was 7.1 ± 0.6 mmol/l. In this study, a total of 243 ECG pathology related to hyperkalemia, 79 of which included main rhythm disorders, and the remaining 164 were nonrhythm disorders in ECG parameters, were analyzed. No statistically significant changes were determined in patients’ nonrhythm ECG disorders with IV Ca-gluconate treatment (P = 0.125). However, nine of the 79 main rhythm disorders due to hyperkalemia improved with calcium gluconate treatment and this change was statistically significant (P < 0.004). CONCLUSION: IV Ca-gluconate therapy was found to be effective, albeit to a limited degree, in main rhythm ECG disorders due to hyperkalemia, but it was not found to be effective in nonrhythm ECG disorders due to hyperkalemia. Therefore, Ca-gluconate may be effective only in the main rhythm disorders due to hyperkalemia.


  • Factors determining ARDS and mortality in Covid-19 pneumonia

    by Adnan Yamanoğlu, Saylav Bora, Nalan Gökçe Çelebi̇ Yamanoğlu, Cüneyt Arikan, Hüseyin Acar

    Introduction COVID-19 is caused by a newly discovered corona virus called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). COVID-19 patients often present with fever, myalgia or fatigue and dry cough. Although most patients' prognosis is thought to be benign, it is known that poor results can be observed in elderly patients and those with chronic underlying diseases. Our aim in this study is to investigate the factors that progress to ARDS and cause mortality in patients with COVID-19 pneumonia, based on symptoms, laboratory findings, Computed Tomography (CT) findings, chronic diseases and continuous medications they use. Material Method Demographic characteristics of patients with Covid-19 pneumonia such as age, gender, complaints, vital signs, physical examination findings, smoking and other habits, chronic disease histories, laboratory and imaging examination results, treatment regimen applied in the hospital, hospitalization and intensive care durations were obtained and recorded in the hospital registration system. Clinical outcomes of all patients; Acute Respiratory Disitress (ARDS) has been recorded by classifying it as discharge or exitus. The definition of ARDS was made according to the Berlin criteria updated in 2012. Result and Conclusion In this study, low oxygen saturation at admission, chronic diuretic use, hypocalcemia, thrombocytopenia were found to be significant parameters that increase the risk for both ARDS and mortality in patients with Covid-19 pneumonia. In addition, high D-Dimer was found to be a significant risk factor for the development of ARDS, while advanced age was found to be a significant risk factor for mortality.

  • The value of the inferior vena cava ultrasound in the decision to hospitalise in patients with acute decompensated heart failure; the best sonographic measurement method?

    by Adnan Yamanoglu, Nalan Gokce Celebi Yamanoglu, Semi Ozturk, Sumeyye Cakmak, Serhat Akay, Pınar Yesim Akyol, Ozgur Sogut

    Objectives: The primary aim of this study was to determine the value of the inferior vena cava (IVC) ultrasound in the decision to hospitalise acute decompensated heart failure (ADHF) patients. Our secondary aim was to find the most successful IVC measurement method in monitoring volume status. Methods: ADHF patients were accepted over a 1-year period in this study. Patients’ vital signs, laboratory tests and IVC measurements measured by six methods (in B- and M-mode; maximum, minimum diameter and caval index) performed on an hourly basis were recorded. The presence of any statistically significant difference between the IVC measurement methods, laboratory tests and vital parameters between the hospitalised and discharged patients was calculated. ROC curves were produced in order to determine the ability of parameters to differentiate two groups. Spearman’s correlation test was used to investigate correlation between the IVC measurement methods and patients’ urine outputs. Results: A total of 71 patients were included in the study; 42 of these were hospitalised and 29 were discharged. Potassium, brain natriuretic peptide, respiration rate, urine output, maximum and minimum IVC diameters differed significantly between the two groups. Minimum IVC diameter measured in M-mode was identified as a weak marker with 65% sensitivity and 64% specificity (+PPV: 73%; −NPV:54%) for hospitalisation. Change in maximum IVC diameter measured in B-mode exhibited a high degree of correlation with change in body fluid (cc: 0.802). Conclusion: IVC ultrasound may have a limited value in the decision to hospitalise ADHF patients. But Maximum IVC diameter may be an ideal method for monitoring hypervolemic patients’ volume status. Clinical Trials Identifier: NCT02725151


  • How much can synthetic cannabinoid damage the heart? A case of cardiogenic shock following resistant ventricular fibrillation after synthetic cannabinoid use

    by Adnan Yamanoglu, Nalan Gokce Celebi Yamanoglu, Tugba Evran, Ozgur Sogut

    New substances are constantly being added to the content of synthetic cannabinoids (SCs). SCs can affect the cardiovascular system and cause hypotension and bradycardia, myocardial infarction, atrial fibrillation, prolonged QTc, and Mobitz type II atrioventricular block. However, no cases associated with ventricular fibrillation (VF) have been reported to date. We report a case of a 26‐year‐old male patient admitted to the emergency department due to altered consciousness after SC use and requiring prolonged cardiopulmonary resuscitation due to resistant VF and cardiogenic shock.